Why the study?
Does TZD use reduce the risk of lung, prostate, and colorectal cancer in male patients with diabetes?
Population
87,678 male patients 40 years and older diagnosed with diabetes mellitus between 1997 and 2003 from 10…
Comparison
Thiazolidinediones (TZDs) vs Nonusers of TZDs
Design
Cohort
Authors
Loading...
TZD use should not yet alter prescribing to reduce cancer risk in diabetes; leaves open a hypothesis-generating lung cancer association needing prospective confirmation.
Does TZD use reduce the risk of lung, prostate, and colorectal cancer in male patients with diabetes?
Thiazolidinedione use in male patients with diabetes is associated with a significantly reduced risk of lung cancer, though not colorectal or prostate cancer.
Govindarajan et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: